Hidradenitis Suppurativa - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Hidradenitis Suppurativa - Pipeline Review, H2 2015’, provides an overview of the Hidradenitis Suppurativa’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hidradenitis Suppurativa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hidradenitis Suppurativa and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hidradenitis Suppurativa and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hidradenitis Suppurativa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hidradenitis Suppurativa pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hidradenitis Suppurativa
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hidradenitis Suppurativa pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hidradenitis Suppurativa Overview 6
Therapeutics Development 7
Pipeline Products for Hidradenitis Suppurativa - Overview 7
Pipeline Products for Hidradenitis Suppurativa - Comparative Analysis 8
Hidradenitis Suppurativa - Therapeutics under Development by Companies 9
Hidradenitis Suppurativa - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Hidradenitis Suppurativa - Products under Development by Companies 13
Hidradenitis Suppurativa - Companies Involved in Therapeutics Development 14
AbbVie Inc. 14
Cellceutix Corporation 15
Delenex Therapeutics AG 16
Johnson & Johnson 17
Novartis AG 18
Hidradenitis Suppurativa - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
adalimumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
adalimumab biosimilar - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CJM-112 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
DLX-105 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
DLX-2751 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Disrupt Cell Membrane for Hidradenitis Suppurativa - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ustekinumab - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Hidradenitis Suppurativa - Recent Pipeline Updates 40
Hidradenitis Suppurativa - Dormant Projects 50
Hidradenitis Suppurativa - Discontinued Products 51
Hidradenitis Suppurativa - Product Development Milestones 52
Featured News & Press Releases 52
Jul 30, 2015: Humira (Adalimumab) Approved By European Commission For Moderate To Severe Hidradenitis Suppurativa 52
Jun 26, 2015: Abbvie's Humira (Adalimumab) Receives Positive Chmp Opinion To Treat Adult Patients With Active Moderate To Severe Hidradenitis Suppurativa, A Chronic Inflammatory Skin Disease 52
May 15, 2015: Abbvie Receives Orphan Drug Designation For Humira (Adalimumab) From The U.S. Food And Drug Administration For The Investigational Treatment Of Moderate-To-Severe Hidradenitis Suppurativa 53
Mar 17, 2015: Abbvie's Dermatology Leadership Showcased With Humira (Adalimumab) Data At American Academy Of Dermatology 2015 Annual Meeting 54
Oct 13, 2014: AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress 55
Sep 11, 2014: AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease 56
Sep 11, 2014: Delenex Announces New Clinical Data 57
Oct 03, 2013: AbbVie Presents Phase II Data Evaluating the Efficacy of HUMIRA in Patients with Hidradenitis Suppurativa 57
Mar 15, 2012: Abbott Announces Patient Enrollment In Two Phase III Studies Of HUMIRA For Moderate To Severe Hidradenitis Suppurativa 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61
List Of Tables
Number of Products under Development for Hidradenitis Suppurativa, H2 2015 7
Number of Products under Development for Hidradenitis Suppurativa - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Hidradenitis Suppurativa - Pipeline by AbbVie Inc., H2 2015 14
Hidradenitis Suppurativa - Pipeline by Cellceutix Corporation, H2 2015 15
Hidradenitis Suppurativa - Pipeline by Delenex Therapeutics AG, H2 2015 16
Hidradenitis Suppurativa - Pipeline by Johnson & Johnson, H2 2015 17
Hidradenitis Suppurativa - Pipeline by Novartis AG, H2 2015 18
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Stage and Target, H2 2015 21
Number of Products by Stage and Mechanism of Action, H2 2015 23
Number of Products by Stage and Route of Administration, H2 2015 25
Number of Products by Stage and Molecule Type, H2 2015 27
Hidradenitis Suppurativa Therapeutics - Recent Pipeline Updates, H2 2015 40
Hidradenitis Suppurativa - Dormant Projects, H2 2015 50
Hidradenitis Suppurativa - Discontinued Products, H2 2015 51
List Of Figures
Number of Products under Development for Hidradenitis Suppurativa, H2 2015 7
Number of Products under Development for Hidradenitis Suppurativa - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 11
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Top 10 Targets, H2 2015 20
Number of Products by Stage and Top 10 Targets, H2 2015 20
Number of Products by Top 10 Mechanism of Actions, H2 2015 22
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 22
Number of Products by Top 10 Routes of Administration, H2 2015 24
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 24
Number of Products by Top 10 Molecule Types, H2 2015 26
Number of Products by Stage and Top 10 Molecule Types, H2 2015 26
